Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleromyxedema.

Clara-Dina Cokonis Georgakis1, Gerald Falasca, Alexander Georgakis

  • 1Division of Dermatology, Cooper University Hospital, Camden, NJ 08103, USA. doctorbeba@hotmail.com

Clinics in Dermatology
|November 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Onycho-oncology: A Useful Neologism.

Journal of the American Academy of Dermatology·2026
Same author

Mitigating the Increasing Squamous Cell Carcinoma Burden.

Journal of the American Academy of Dermatology·2026
Same author

The wide world of glucagon-like peptide-1 agonist therapy: The thrill of weight loss and the agony of alopecia.

Journal of the American Academy of Dermatology·2026
Same author

Spironolactone rules.

Journal of the American Academy of Dermatology·2026
Same author

Visual recognition and medical dermatology learning needs identified through continuing certification program assessments of the American Board of Dermatology.

Journal of the American Academy of Dermatology·2026
Same author

Mitigating dermatologic malpractice risk: Dueling the sword of Damocles.

Journal of the American Academy of Dermatology·2026
Same journal

Letter to the editor in reply to "Ethics of Rising Trends in Dermatology Publications Using Large-Scale Databases".

Clinics in dermatology·2026
Same journal

Ethics of suggesting image-guided superficial radiation therapy on the pathology report.

Clinics in dermatology·2026
Same journal

Tanorexia: The Psychodermatology of Compulsive Tanning.

Clinics in dermatology·2026
Same journal

Ear manifestations of connective tissue diseases: A dermatologic, histopathologic, and clinicopathologic review.

Clinics in dermatology·2026
Same journal

Discovery of an intravenous drug injection site: A meticulous cutaneous examination provides the forensic dermatologic clue to a diagnosis of homicide.

Clinics in dermatology·2026
Same journal

Sherlock Holmes and the mystery of the deadly diet.

Clinics in dermatology·2026
See all related articles

Scleromyxedema is a rare skin disease with unknown causes, often linked to paraproteins. Current treatments show promise but require further research for proven efficacy in managing this condition.

Area of Science:

  • Dermatology
  • Immunology
  • Pathology

Background:

  • Scleromyxedema is a rare mucinous skin disease.
  • Characterized by a generalized papular sclerodermoid eruption and systemic issues.
  • Associated with significant morbidity and mortality.

Purpose of the Study:

  • To review the etiology and treatment of scleromyxedema.
  • To highlight the potential role of paraproteins and non-paraprotein factors.
  • To discuss current treatment modalities and the need for further research.

Main Methods:

  • Literature review of scleromyxedema.
  • Analysis of proposed etiological factors.
  • Summary of suggested treatment options.

Related Experiment Videos

Main Results:

  • Etiology of scleromyxedema remains largely unknown.
  • Paraproteins are implicated, but non-paraprotein factors may also contribute.
  • Several treatments like melphalan, cyclophosphamide, interferon alfa, and plasmapheresis have been suggested.

Conclusions:

  • Further research is essential to establish effective treatments for scleromyxedema.
  • Understanding the pathogenesis is key to developing targeted therapies.
  • Improved treatment strategies are needed to reduce morbidity and mortality.